Table 1.
Frequencies of HER2/HR Status among women aged 20–49 years diagnosed with stage I-III breast cancer, 2010–2016 SEER 18 registries
| 20–29 Years | 30–39 Years | 40–49 Years | ||||
|---|---|---|---|---|---|---|
| N | % | N | % | N | % | |
| Analytic sample | 1,818 | 14,550 | 52,162 | |||
| HER2+/HR+ | 385 | 21.2 | 2,677 | 18.4 | 6,935 | 13.3 |
| HER2+/HR− | 133 | 7.3 | 1,041 | 7.2 | 2,607 | 5.0 |
| HER2−/HR+ | 879 | 48.4 | 8,008 | 55.0 | 36,021 | 69.1 |
| HER2−/HR− | 421 | 23.2 | 2,824 | 19.4 | 6,599 | 12.7 |
| Stage I | 476 | 4,191 | |23,093 | |||
| HER2+/HR+ | 106 | 22.3 | 708 | 16.9 | 2,549 | 11.0 |
| HER2+/HR− | 34 | 7.1 | 243 | 5.8 | 837 | 3.6 |
| HER2−/HR+ | 265 | 55.7 | 2,657 | 63.4 | 17,791 | 77.0 |
| HER2−/HR− | 71 | 14.9 | 583 | 13.9 | 1,916 | 8.3 |
| Stage II | 930 | 7,334 | 21,268 | |||
| HER2+/HR+ | 199 | 21.4 | 1,397 | 19.0 | 3,136 | 14.7 |
| HER2+/HR− | 62 | 6.7 | 494 | 6.7 | 1,148 | 5.4 |
| HER2−/HR+ | 423 | 45.5 | 3,770 | 51.4 | 13,510 | 63.5 |
| HER2−/HR− | 246 | 26.5 | 1,673 | 22.8 | 3,474 | 16.3 |
| Stage III | 412 | 3,025 | 7,801 | |||
| HER2+/HR+ | 80 | 19.4 | 572 | 18.9 | 1,250 | 16.0 |
| HER2+/HR− | 37 | 9.0 | 304 | 10.1 | 622 | 8.0 |
| HER2−/HR+ | 191 | 46.4 | 1,581 | 52.3 | 4,720 | 60.5 |
| HER2−/HR− | 104 | 25.2 | 568 | 18.8 | 1,209 | 15.5 |
| Non-Hispanic white | 903 | 7,503 | 30,282 | |||
| HER2+/HR+ | 207 | 22.9 | 1,455 | 19.4 | 3,863 | 12.8 |
| HER2+/HR− | 70 | 7.8 | 525 | 7.0 | 1,278 | 4.2 |
| HER2−/HR+ | 438 | 48.5 | 4,190 | 55.8 | 21,761 | 71.9 |
| HER2−/HR− | 188 | 20.8 | 1,333 | 17.8 | 3,380 | 11.2 |
| Non-Hispanic black | 308 | 2,090 | 6,253 | |||
| HER2+/HR+ | 52 | 16.9 | 365 | 17.5 | 817 | 13.1 |
| HER2+/HR− | 21 | 6.8 | 136 | 6.5 | 422 | 6.7 |
| HER2−/HR+ | 143 | 46.4 | 1,032 | 49.4 | 3,598 | 57.5 |
| HER2−/HR− | 92 | 29.9 | 557 | 26.7 | 1,416 | 22.6 |
| Non-Hispanic Asian or Pacific Islander | 184 | 1,824 | 6,353 | |||
| HER2+/HR+ | 44 | 23.9 | 326 | 17.9 | 909 | 14.3 |
| HER2+/HR− | 13 | 7.1 | 134 | 7.3 | 387 | 6.1 |
| HER2−/HR+ | 93 | 50.5 | 1,117 | 61.2 | 4,532 | 71.3 |
| HER2−/HR− | 34 | 18.5 | 247 | 13.5 | 525 | 8.3 |
| Hispanic (all races) | 398 | 2,937 | 8,701 | |||
| HER2+/HR+ | 74 | 18.6 | 494 | 16.8 | 1,262 | 14.5 |
| HER2+/HR− | 27 | 6.8 | 224 | 7.6 | 491 | 5.6 |
| HER2−/HR+ | 195 | 49.0 | 1,572 | 53.5 | 5,741 | 66.0 |
| HER2−/HR− | 102 | 25.6 | 647 | 22.0 | 1,207 | 13.9 |
Abbreviations: HER2, human epidermal growth factor receptor-2; HR, hormone receptor; SEER, Surveillance, Epidemiology, and End Results.
Results for non-Hispanic American Indian/Alaska Native women aged 20–49 years (n=435) and non-Hispanic women of unknown race aged 20–49 years (n=359) were not presented due to sparse totals for these strata.
Because of rounding, percentages might not total 100.